Lorem ipsum dolor sit amet consectetur adipisicing elit. Quidem esse placeat, maiores officiis nisi, rerum porro exercitationem voluptas dolorem vel totam incidunt ex delectus optio eum veniam. Qui, voluptate quae?

  • Jimenez-Fonseca P, Alberto Carmona-Bayonas A, Martínez de Castro E, Gallego J. Confirmation of the external validity of clinical trials in ever-changing target populations and time conditions: the example of docetaxel in advanced gastric cancer. April 2020. Epud ahead of print.
  • Wagner AD, Syn NLX, Moehler M, Grothe W, Yong WP, Tai B, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064.
  • Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-7.

Disclaimer: This tool is intended for use by healthcare professionals only. Patients with advanced gastric cancer should seek medical care. Physicians and other healthcare professionals who use the Agamenon Triplet calculator should exercise their own clinical judgment. This app does not provide professional advice. We have exercised great caution in creating this app, based on real-world data. However, medical standards and practice may vary as new information becomes available and professionals should consult a variety of medical sources. While we estimate survival probability for advanced gastric cancer patients undergoing first-line chemotherapy, we in no way endorse any particular management strategy. Your reliance upon predictions obtained through this app is solely at your own risk. We assume no liability or responsibility whatsoever for damage or injury (including death) to you or anyone else from the use of this tool.